Patents by Inventor John Andrew Chaddock
John Andrew Chaddock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10744190Abstract: The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognised and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.Type: GrantFiled: April 28, 2016Date of Patent: August 18, 2020Assignee: IPSEN BIOINNOVATION LIMITEDInventors: John Andrew Chaddock, Keith Alan Foster
-
Patent number: 9849163Abstract: The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognized and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.Type: GrantFiled: December 16, 2009Date of Patent: December 26, 2017Assignee: Ipsen Bioinnovation LimitedInventors: John Andrew Chaddock, Keith Alan Foster
-
Publication number: 20160279208Abstract: The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognised and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.Type: ApplicationFiled: April 28, 2016Publication date: September 29, 2016Inventors: John Andrew CHADDOCK, Keith Alan FOSTER
-
Publication number: 20140348828Abstract: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.Type: ApplicationFiled: August 14, 2014Publication date: November 27, 2014Inventors: Keith Alan FOSTER, John Andrew CHADDOCK, Conrad Padraig QUINN, John Robert PURKISS
-
Patent number: 8852603Abstract: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.Type: GrantFiled: January 6, 2012Date of Patent: October 7, 2014Assignee: Syntaxin LimitedInventors: Keith Alan Foster, John Andrew Chaddock, Conrad Padraig Quinn, John Robert Purkiss
-
Publication number: 20120128649Abstract: The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognised and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.Type: ApplicationFiled: December 16, 2009Publication date: May 24, 2012Applicant: SYNTAXIN LIMITEDInventors: John Andrew Chaddock, Keith Alan Foster
-
Publication number: 20120101027Abstract: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.Type: ApplicationFiled: January 6, 2012Publication date: April 26, 2012Applicant: SYNTAXIN LIMITEDInventors: Keith Alan FOSTER, John Andrew CHADDOCK, Conrad Padraig QUINN, John Robert PURKISS
-
Publication number: 20110152174Abstract: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.Type: ApplicationFiled: February 7, 2011Publication date: June 23, 2011Applicant: SYNTAXIN LIMITEDInventors: Keith Alan FOSTER, John Andrew CHADDOCK, Conrad Padraig QUINN, John Robert PURKISS
-
Patent number: 7452543Abstract: A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibers. They comprise a galactose-binding lectin linked to a derivative of a clostridial neurotoxin. The derivative of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. The agents may be used in or as pharmaceuticals for the treatment of pain, particular chronic pain.Type: GrantFiled: October 25, 2005Date of Patent: November 18, 2008Assignee: Syntaxin Ltd.Inventors: John Andrew Chaddock, Philip Marks, Michael John Duggan
-
Patent number: 7208466Abstract: The present invention relates to the treatment of pain and to compounds that modulate C-fibre activity. In particular, the present invention relates to the use of a lectin in the manufacture of a medicament for modulation of C-fibre neuron activity, and to lectin conjugates. The lectin conjugates comprise a lectin coupled to a peptide or protein, wherein the peptide or protein is substantially free of Clostridial neurotoxin enzyme activity. The present invention also concerns methods for manufacturing conjugates. The compounds and compositions described have particular application in the treatment of diseases of which C-fibre activity is a component. Such diseases include pain, inflamation, psoriasis and other C-fibre related conditions.Type: GrantFiled: March 31, 2000Date of Patent: April 24, 2007Assignee: The Health Protection AgencyInventors: Keith Alan Foster, John Andrew Chaddock, Conrad Padraig Quinn
-
Patent number: 7193066Abstract: Toxin derivatives are prepared by proteolytic treatment of holotoxin, and their toxicity is reduced by contacting the preparation with a ligand, which can be a metal or an antibody or another ligand. This ligand selectively binds to the toxin but not to the toxin derivative. Removing the ligand and toxin bound to the ligand further reduces toxicity. A second ligand is used to remove conjugates of the toxin and the first ligand. Compositions contain the purified derivative, optionally plus the toxin and the ligand.Type: GrantFiled: September 13, 2000Date of Patent: March 20, 2007Assignee: The Health Protection AgencyInventors: John Andrew Chaddock, Frances Celine Gail Alexander, Keith Alan Foster
-
Patent number: 7052702Abstract: A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibers. They comprise a galactose-binding lectin linked to a derivative of a clostridial neurotoxin. The derivative of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. The agents may be used in or as pharmaceuticals for the treatment of pain, particularly chronic pain.Type: GrantFiled: October 7, 1998Date of Patent: May 30, 2006Assignees: Health Protection Agency, Ipsen LimitedInventors: Michael John Duggan, John Andrew Chaddock
-
Patent number: 6632440Abstract: A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the treatment of hypersecretion of mucus, which inhibits mucus secretion by inhibiting mucus secreting cells, and/or inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.Type: GrantFiled: May 29, 2001Date of Patent: October 14, 2003Assignee: Health Protection AgencyInventors: Conrad Padraig Quinn, Keith Alan Foster, John Andrew Chaddock
-
Publication number: 20030180289Abstract: A method of treatment of disease by inhibition of cellular secretory processes is provided. The method has particular application in the treatment of diseases dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system, and bone cells. Agents and compositions therefor, as well as methods for manufacturing these agents and compositions, are provided. In a preferred embodiment a clostridial neurotoxin, substantially devoid of holotoxin binding affinity for neuronal cells of the presynaptic muscular junction, is associated with a targeting moiety. The targeting moiety is selected such that the clostridial toxin conjugate so formed may be directed to a non-neuronal target cell to which the conjugate may bind. Following binding, a neurotoxin component of the conjugate, which is capable of inhibition of cellular secretion, passes into the cytosol of the target cell by cellular internalisation mechanisms.Type: ApplicationFiled: August 14, 2002Publication date: September 25, 2003Inventors: Keith Alan Foster, John Andrew Chaddock, Conrad Padraig Quinn, John Robert Purkiss